​

Mineralys Therapeutics Ownership | Who Owns Mineralys Therapeutics?

OverviewForecastFinancialsChartTranscripts

Mineralys Therapeutics Ownership Summary

Mineralys Therapeutics is owned by 15.57% institutional investors, 0.72% insiders, and 83.71% retail investors. Catalys pacific is the largest institutional shareholder, holding 11.68% of MLYS shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.40% of its assets in Mineralys Therapeutics shares.

MLYS Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMineralys Therapeutics15.57%0.72%83.71%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Catalys pacific7.90M11.68%$214.11M
Ra capital management7.69M11.37%$208.40M
Samsara biocapital5.87M8.68%$159.05M
Fmr4.86M7.18%$131.69M
Blackrock funding, inc. /de4.48M6.62%$121.41M
Wellington management group llp3.36M4.96%$91.00M
Vanguard group3.35M4.75%$121.68M
State street2.94M4.34%$79.53M
Caligan partners lp2.77M4.10%$75.11M
Laurion capital management lp2.23M3.30%$60.47M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Catalys pacific7.90M92.81%$214.11M
Andera partners1.59M24.38%$43.13M
Samsara biocapital5.87M15.45%$159.05M
22nw, lp444.32K8.25%$12.04M
Sphera funds management1.34M5.76%$36.30M
Caligan partners lp2.77M5.00%$75.11M
Sr one capital management, lp1.56M4.63%$42.37M
Davern capital partners, lp447.15K3.32%$12.11M
Stempoint capital lp533.38K2.81%$14.45M
Laurion capital management lp2.23M2.64%$60.47M

Top Buyers

HolderShares% AssetsChange
Wellington management group llp3.36M0.02%2.57M
Orbimed advisors2.05M1.11%1.07M
Sphera funds management1.34M5.76%890.97K
Nantahala capital management895.48K0.89%782.20K
Point72 asset management1.91M0.07%704.21K

Top Sellers

HolderShares% AssetsChange
Tcg crossover management---2.47M
Holocene advisors, lp---1.60M
Samlyn capital---1.30M
Janus henderson group19.85K0.00%-1.19M
Capital investors---1.16M

New Positions

HolderShares% AssetsChangeValue
Troluce capital advisors655.00K1.09%655.00K$17.74M
Nearwater capital markets450.00K0.23%450.00K$17.06M
Capital world investors398.18K0.00%398.18K$10.79M
Vanguard fiduciary trust375.26K0.00%375.26K$10.17M
Adage capital partners gp105.00K0.01%105.00K$3.98M

Sold Out

HolderChange
National bank of canada /fi/-7.00
Federated hermes-21.00
Signaturefd-22.00
Skopos labs-26.00
Golden state wealth management-32.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202672-69.75%10,534,267-88.08%150.10%40-70.59%18-75.34%
Dec 31, 2025143-28.50%40,919,125-48.50%570.39%86-23.89%44-29.03%
Sep 30, 202519315.57%76,304,72316.16%1161.16%109-9.17%59118.52%
Jun 30, 20251663.75%65,673,2177.91%1000.77%1199.17%27-3.57%
Mar 31, 202515948.60%60,569,32731.79%1131.35%107-28-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF1.98M2.40%-14.08K
Vanguard Health Care Inv1.86M2.25%1.86M
Vanguard Total Stock Mkt Idx Inv1.78M2.16%4.14K
Polar Capital Biotech S Inc1.42M1.72%-
iShares Russell 2000 ETF1.12M1.36%9.45K
Fidelity Select Health Care1.00M1.21%-
Franklin Biotechnology Discv A(acc)USD983.24K1.19%-90.76K
HBM Healthcare Investments AG Ord781.86K0.95%-249.70K
American Century Small Cap Growth Inv679.60K0.82%-33.47K
American Century U.S. Small Cap Growth679.60K0.82%-33.47K

Recent Insider Transactions

DateNameRoleActivityValue
May 18, 2026Rodman David Malcom Chief Medical OfficerSell$11.49K
May 11, 2026Rodman David Malcom Chief Medical OfficerSell$64.50K
May 13, 2026Rodman David Malcom Chief Medical OfficerSell$401.79K
May 12, 2026Rodman David Malcom Chief Medical OfficerSell$186.35K
Apr 17, 2026Rodman David Malcom Chief Medical OfficerSell$13.03K

Insider Transactions Trends

DateBuySell
2026 Q2-9
2026 Q1227
2025 Q4-28
2025 Q3210
2025 Q2-9

MLYS Ownership FAQ

Who Owns Mineralys Therapeutics?

Mineralys Therapeutics shareholders are primarily institutional investors at 15.57%, followed by 0.72% insiders and 83.71% retail investors. The average institutional ownership in Mineralys Therapeutics's industry, Biotech Stocks , is 35.75%, which Mineralys Therapeutics falls below.

Who owns the most shares of Mineralys Therapeutics?

Mineralys Therapeutics’s largest shareholders are Catalys pacific (7.9M shares, 11.68%), Ra capital management (7.69M shares, 11.37%), and Samsara biocapital (5.87M shares, 8.68%). Together, they hold 31.73% of Mineralys Therapeutics’s total shares outstanding.

Does Blackrock own Mineralys Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Mineralys Therapeutics.

Who is Mineralys Therapeutics’s biggest shareholder by percentage of total assets invested?

Catalys pacific is Mineralys Therapeutics’s biggest shareholder by percentage of total assets invested, with 92.81% of its assets in 7.9M Mineralys Therapeutics shares, valued at 214.11M$.

Who is the top mutual fund holder of Mineralys Therapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Mineralys Therapeutics shares, with 2.40% of its total shares outstanding invested in 1.98M Mineralys Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools